Cefepime

Structural formula
General
Surname	Cefepime
Molecular formula	C 19 H 24 N 6 O 5 S 2
External identifiers / databases
EC number	643-019-5
ECHA InfoCard	100.171.025
PubChem	5479537
ChemSpider	4586395
DrugBank	DB01413
Wikidata	Q2552927
Drug information
ATC code	J01 DE01
properties
Molar mass	480.56 g mol −1
safety instructions
	Please note the exemption from the labeling requirement for drugs, medical devices, cosmetics, food and animal feed
GHS labeling of hazardous substances danger
H and P phrases	H: 317-334
	P: ?
	As far as possible and customary, SI units are used. Unless otherwise noted, the data given apply to standard conditions .

Cefepime is an antibiotic from the group of cephalosporins . The bactericidal effect is, as with other β-lactam antibiotics by inhibiting bacterial cell wall synthesis. As a 4th generation cephalosporin, cefepime is also effective against Pseudomonas aeruginosa .

Cefepime was developed by Bristol-Myers Squibb and received approval in the United States in January 1996 for the treatment of moderate to severe pneumonia . Approval in Germany has been in place since 2004, the trade name is maxim , and there are now various generics . Indications for use are bacteremia associated with severe pneumonia, severe urinary tract infection, or abdominal infections, including peritonitis .

Very often the direct Coombs test (test to determine antibodies on red blood cells) can be false positive after administration of cefepime . Possible side effects include gastrointestinal complaints, bleeding disorders, changes in the blood count, headache, fever, pseudomembranous colitis and allergic reactions.

literature

SV Burgess, VH Mabasa, I. Chow, MH Ensom: Evaluating outcomes of alternative dosing strategies for cefepime: a qualitative systematic review. In: The Annals of pharmacotherapy. Volume 49, number 3, March 2015, pp. 311-322, doi : 10.1177 / 1060028014564179 , PMID 25575975 (review).
EE Adderson, PM Flynn, JM Hoffman: Efficacy and safety of cefepime in pediatric patients: a systematic review and meta-analysis. In: The Journal of pediatrics. Volume 157, Number 3, September 2010, pp. 490-5, 495.e1, doi : 10.1016 / j.jpeds.2010.03.023 , PMID 20434167 (review).
A. Endimiani, F. Perez, RA Bonomo: Cefepime: a reappraisal in an era of increasing antimicrobial resistance. In: Expert review of anti-infective therapy. Volume 6, number 6, December 2008, pp. 805-824, doi : 10.1586 / 14787210.6.6.805 , PMID 19053894 , PMC 2633657 (free full text) (review).

Individual evidence

↑ Template: CL Inventory / not harmonized There is not yet a harmonized classification for this substance . What is shown is a labeling of 1 - [[(6R, 7R) -7 - [[(2Z) -2- (2-amino-4-thiazolyl) -2- (methoxyimino) acetyl] amino] Template: link text check / apostrophe derived from a self-classification by the distributor -2-carboxy-8-oxo-5-thia-1-azabicyclo [4.2.0] oct-2-en-3-yl] methyl] -1-methyl-pyrrolidinium, inner salt in the Classification and Labeling Inventory of the European Chemicals Agency (ECHA), accessed October 29, 2018.

↑ RH Barbhaiya, ST Forgue u. a .: Safety, tolerance, and pharmacokinetic evaluation of cefepime after administration of single intravenous doses. In: Antimicrobial agents and chemotherapy. Volume 34, Number 6, June 1990, pp. 1118-1122, PMID 2203303 , PMC 171768 (free full text).

↑ Clinical Review: Cefepime. As of January 20, 2009, p. 7 (PDF).

^ Marianne Abele-Horn: Antimicrobial Therapy. Decision support for the treatment and prophylaxis of infectious diseases. With the collaboration of Werner Heinz, Hartwig Klinker, Johann Schurz and August Stich, 2nd, revised and expanded edition. Peter Wiehl, Marburg 2009, ISBN 978-3-927219-14-4 , p. 340.

[1] Template: CL Inventory / not harmonized There is not yet a harmonized classification for this substance . What is shown is a labeling of 1 - [[(6R, 7R) -7 - [[(2Z) -2- (2-amino-4-thiazolyl) -2- (methoxyimino) acetyl] amino] Template: link text check / apostrophe derived from a self-classification by the distributor -2-carboxy-8-oxo-5-thia-1-azabicyclo [4.2.0] oct-2-en-3-yl] methyl] -1-methyl-pyrrolidinium, inner salt in the Classification and Labeling Inventory of the European Chemicals Agency (ECHA), accessed October 29, 2018.

[PMID2203303-2] RH Barbhaiya, ST Forgue u. a .: Safety, tolerance, and pharmacokinetic evaluation of cefepime after administration of single intravenous doses. In: Antimicrobial agents and chemotherapy. Volume 34, Number 6, June 1990, pp. 1118-1122, PMID 2203303 , PMC 171768 (free full text).

[3] Clinical Review: Cefepime. As of January 20, 2009, p. 7 (PDF).

[4] Marianne Abele-Horn: Antimicrobial Therapy. Decision support for the treatment and prophylaxis of infectious diseases. With the collaboration of Werner Heinz, Hartwig Klinker, Johann Schurz and August Stich, 2nd, revised and expanded edition. Peter Wiehl, Marburg 2009, ISBN 978-3-927219-14-4 , p. 340.